- Home
- GOVX vs NCPL Comparison
GOVX vs NCPL Comparison
Compare GOVX & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOVX | NCPL |
|---|---|---|
| Founded | 2001 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GOVX | NCPL |
|---|---|---|
| Price | $2.77 | $0.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $103.00 | N/A |
| AVG Volume (30 Days) | 194.5K | ★ 1.7M |
| Earning Date | 11-13-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,353,560.00 | $797,839.00 |
| Revenue This Year | N/A | $739.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $2.61 | $0.61 |
| 52 Week High | $53.73 | $8.75 |
Technical Indicators
Market Signals| Indicator | GOVX | NCPL |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 45.15 |
| Support Level | $2.72 | $0.69 |
| Resistance Level | $3.42 | $0.80 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 61.95 | 52.21 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.